Literature DB >> 24833529

ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.

Xiaobo Lu1, Sha Xiao, Cuihong Jin, Tahar van der Straaten, Xiaoxia Li.   

Abstract

Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy. The relevant cohort studies were identified by searching the electronic databases of MEDLINE, EMBASE, and CNKI. We used ''colorectal,'' ''cancer,'' ''carcinoma,'' ''ERCC1,'' ''XPD or ERCC2,'' ''polymorphism,'' ''oxaliplatin,'' ''treatment,'' or ''chemotherapy'' as key words. Inclusion criteria were patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, evaluation of polymorphism of ERCC1 and XPD/ ERCC2, and overall response rate (ORR). In this meta-analysis, a total of seven studies were selected according to the inclusion criteria. Five studies investigated ERCC1 codon 118 polymorphisms and three studies evaluated XPD/ERCC2 codon 751 polymorphisms. For ERCC1 codon C118T polymorphism, the ORR to oxaliplatin-based chemotherapy in patients with C/C wild genotype was 77.27% and it was 69.30% for C/T and T/T variant genotype. The pooled odds ratio (OR) for C/C wild-type vs. C/T and T/T genotype was 1.11 (95% CI, 0.86-1.42; P = 0.42). For XPD/ERCC2 Lys751Gln polymorphism, the response rate was 86.58 and 67.57% in patients with the A/A and either one or two C alleles (A/C or C/C) respectively, and the pooled OR was 1.15 (95% CI, 1.01-1.30; P = 0.03). Furthermore, we chose subgroup analysis in order to find the difference between the Caucasian and Asian ethnicity. The results indicated that Oxaliplatin sensitivity was significantly associated with ERCC1 C118T polymorphism in Asian people. XPD/ERCC2 Lys751Gln polymorphism had the predictive value especially for the patients from the America and Europe.
© 2012 Wiley Periodicals, Inc.

Entities:  

Keywords:  ERCC1 XPD/ERCC2; Meta-analysis; colorectal cancer; oxaliplatin-based chemotherapy; polymorphism

Mesh:

Substances:

Year:  2012        PMID: 24833529      PMCID: PMC6807459          DOI: 10.1002/jcla.20494

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  25 in total

Review 1.  Polymorphisms in DNA repair genes and associations with cancer risk.

Authors:  Ellen L Goode; Cornelia M Ulrich; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-12       Impact factor: 4.254

2.  Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer.

Authors:  Victor Moreno; Federica Gemignani; Stefano Landi; Lydie Gioia-Patricola; Amélie Chabrier; Ignacio Blanco; Sara González; Elisabet Guino; Gabriel Capellà; Federico Canzian
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

3.  A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

Authors:  D J Park; J Stoehlmacher; W Zhang; D D Tsao-Wei; S Groshen; H J Lenz
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 4.  Nucleotide excision repair: from E. coli to man.

Authors:  C Petit; A Sancar
Journal:  Biochimie       Date:  1999 Jan-Feb       Impact factor: 4.079

Review 5.  Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.

Authors:  Shu-zhen Wei; Ping Zhan; Mei-qi Shi; Yi Shi; Qian Qian; Li-ke Yu; Yong Song
Journal:  Med Oncol       Date:  2010-02-09       Impact factor: 3.064

6.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Authors:  Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz
Journal:  J Clin Oncol       Date:  2001-12-01       Impact factor: 44.544

7.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

8.  ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

Authors:  David J Park; Wu Zhang; Jan Stoehlmacher; Denice Tsao-Wei; Susan Groshen; Ji Gil; Jim Yun; Erin Sones; Nalin Mallik; Heinz-Josef Lenz
Journal:  Clin Adv Hematol Oncol       Date:  2003-03

9.  Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.

Authors:  Mariano Monzo; Isabel Moreno; Alfons Navarro; Rafael Ibeas; Rosa Artells; Bernat Gel; Francisco Martinez; Jose Moreno; Raquel Hernandez; Marta Navarro-Vigo
Journal:  Oncology       Date:  2008-01-17       Impact factor: 2.935

10.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

View more
  2 in total

Review 1.  Molecular testing to optimize therapeutic decision making in advanced colorectal cancer.

Authors:  Thomas J Semrad; Edward J Kim
Journal:  J Gastrointest Oncol       Date:  2016-04

2.  Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.

Authors:  Hamideh Salimzadeh; Elinor Bexe Lindskog; Bengt Gustavsson; Yvonne Wettergren; David Ljungman
Journal:  BMC Cancer       Date:  2020-05-12       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.